The Carlyle Group reports its Q1 2026 results this morning with the most notable pre-print signal coming not from the lending market or options positioning, but from its own executive suite — where insiders have been steady sellers throughout the first quarter.
The insider picture is hard to ignore. Founder and Chairman David Rubenstein sold 500,000 shares at $46.68 in mid-March, a $23.3 million transaction. CEO Harvey Schwartz sold 134,812 shares at $54.49 in February. Both Co-Presidents, the CFO, COO, and Chief Accounting Officer also registered sales on February 6 — a cluster of nine separate transactions on a single day that collectively totalled well over $15 million. Net insider activity over the trailing 90 days amounts to over $85 million in net sales across roughly 1.6 million shares. These were sales into what was then a higher price; the stock has since retreated to $50.80, roughly 8% below the February transaction levels.
The analyst community has been trimming rather than cutting. Goldman Sachs lowered its target from $81 to $69 on April 7 while holding its Buy rating — a meaningful reduction that signalled growing caution on the valuation trajectory. JPMorgan followed on April 30, nudging its target down to $66 while staying Neutral. Morgan Stanley also shaved its target, to $66 from $71. Against this, Evercore ISI went against the grain, raising its target to $56 from $52 with an In-Line rating. The consensus mean sits at $61.81, implying roughly 22% upside from the current price — a positive gap, though the direction of recent revisions has been uniformly downward from the more bullish shops. Bulls point to Carlyle's $474 billion AUM and the scale of its global credit platform at $208.5 billion as structural pillars supporting long-term fee growth. Bears note near-term uncertainty around realisation activity and the pace of fundraising in the current rate environment.
Short positioning offers little drama as a standalone story. Short interest is 4.3% of the free float — notable but not extreme — and has edged up about 4.6% over the past week. Availability in the lending pool remains loose, with borrow costs barely above 0.40% APR and utilisation well below half its 52-week peak. Options positioning is similarly calm: the put/call ratio is 0.51, essentially in line with its 20-day average of 0.50 and carrying a z-score close to zero. Neither short sellers nor options markets are expressing unusual conviction heading into today's print. The stock itself has recovered 6.3% over the past week and 9.1% over the past month, clawing back some of the year-to-date decline of roughly 15%. Closest peer TPG rose 7.4% on the week; BX and KKR lagged, both up less than 1% — suggesting the recent move in CG has been stock-specific rather than a pure sector tailwind.
Today's print is less about whether Carlyle is managing a large book and more about whether fee-related earnings and realisation activity are tracking ahead of sharply reduced analyst estimates — and whether management's capital-allocation narrative can shift the focus away from a quarter of near-universal insider selling.
See the live data behind this article on ORTEX.
Open CG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
